Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11127607 on NIH RePORTER |
What this research studies
Mantle cell lymphoma (MCL) is a challenging cancer where current treatments, like ibrutinib, often stop working over time. We are exploring why some MCL cells become resistant to these drugs by focusing on a specific protein called CEACAM1, which appears to be very important for MCL cells to grow. By understanding how CEACAM1 helps cancer cells, we hope to find new targets for medicines that could offer better options for patients. This work could lead to new treatments that overcome drug resistance and improve outcomes for those with MCL.
Who could benefit from this research
Good fit: This foundational research is for patients with mantle cell lymphoma who are interested in the development of future treatment options, especially those facing drug resistance.
Not a fit: Patients seeking immediate new treatments or direct clinical trial participation may not find direct benefit from this early-stage laboratory research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments for mantle cell lymphoma, particularly for patients who have become resistant to existing therapies.
How similar studies have performed: While the specific role of CEACAM1 in MCL is a novel focus, understanding cancer cell signaling has successfully led to effective treatments for other lymphomas.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Ngo, Vu Nguyen — Beckman Research Institute/city of Hope
- Study coordinator: Ngo, Vu Nguyen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.